Current Report Filing (8-k)
March 20 2020 - 11:44AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D. C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15 (d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): March 20, 2020
Immune
Therapeutics, Inc.
(Exact
Name of Registrant as Specified in its Charter)
Florida
|
|
000-54933
|
|
59-3226705
|
(State
or other jurisdiction
of
Incorporation)
|
|
(Commission
File
Number)
|
|
(I.R.S.
Employer
Identification
Number)
|
2431
Aloma Ave #124 Winter Park, FL 32792
|
(Address
of principal executive offices)
|
888-613-8802
(Issuer’s
telephone number)
(Former
name, former address and former fiscal year, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provision (see General Instruction A.2 below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock
|
|
OTCMKTS
|
|
IMUN
|
ITEM
7.01 Regulation Fair Disclosure
Effective
as of March 17, 2020, the Immune Therapeutics, Inc., a Florida Company signed a binding letter of intent with a private company
Cytocom, Inc that sets forth the preliminary terms and conditions of a potential collaboration agreement for the development of
Lodonal™ and IRT-101 for use against COVID-19.
ITEM
8.01. OTHER EVENTS
On
March 20, 2020 Immune Therapeutics, Inc. issued a press release announcing a letter of intent that was signed with Cytocom, Inc.
to develop Lodonal™ and other drugs for COVID-19. Immune Therapeutics and Cytocom are planning to work with federal agencies
to seek fast-track approval using Lodonal™ as a way to prevent or treat COVID-19 in high-risk groups who are infected with
2019-nCoV at clinical research centers across the country. IMUN is currently designing studies using Lodonal™ and IRT-101
as a monotherapy or in conjunction with other potential treatments.
The
press release also stated that the Company is in the process of finalizing its development program for ITX401 for pancreatic cancer
and that the Company anticipates submitting a request in April for a Type C meeting with the FDA to discuss the phase III clinical
program for ITX401 treatment of pancreatic cancer. IMUN also expects to initiate testing on the use of Lodonal™ and ITX401
with other approved cancer drugs like Keytruda® and Opvido® in partnership with CYTO to determine the probability of enhancing
the safety and efficacy of these already approved cancer drugs.
ITEM
9.01. FINANCIAL STATEMENTS AND EXHIBITS
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Immune
Therapeutics Inc
(Registrant)
By:
|
/s/
Michael K Handley
|
|
|
Michael
K. Handley
|
|
|
Chief
Executive Officer
|
|
|
|
|
Date:
|
March
20, 2020
|
|
Immune Therapeutics (PK) (USOTC:IMUN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Immune Therapeutics (PK) (USOTC:IMUN)
Historical Stock Chart
From Apr 2023 to Apr 2024